168619-25-8

Basic information

• Product Name: 3'-AMINO-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER
• Synonyms: METHYL 3'-AMINO[1,1'-BIPHENYL]-3-CARBOXYLATE;METHYL 3'-AMINO[1,1'-BIPHENYL]-3-CARBOXYLATE HYDROCHLORIDE;3'-AMINO-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER;3'-AMINO-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE;AKOS BAR-0133;[1,1'-Biphenyl]-3-carboxylicacid, 3'-aMino-, Methyl ester;3'-Amino-[1,1'-biphenyl]-3-carboxylic acid methyl ester;Methyl 3'-aminobiphenyl-3-carboxylate
• CAS NO: 168619-25-8
• Molecular Formula: C₁₄H₁₃NO₂
• Molecular Weight: 227.26
• Mol File: 168619-25-8.mol

Chemical Properties

• Boiling Point: 423℃
• Flash Point: 251℃
• Appearance: /
• Density: 1.166
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Very Slightly)
• CAS DataBase Reference: 3'-AMINO-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-AMINO-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER(168619-25-8)
• EPA Substance Registry System: 3'-AMINO-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER(168619-25-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 168619-25-8(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
3'-AMINO-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER is used as a reagent for organic synthesis to facilitate the creation of various chemical compounds. Its unique structure makes it a valuable component in the development of new molecules and materials.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3'-AMINO-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER is used as a building block for the development of new drugs. Its properties can be harnessed to create molecules with specific therapeutic effects, contributing to the advancement of medical treatments.
Used in Research and Development:
3'-AMINO-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER is also utilized in research and development settings, where it can be employed to study the properties and interactions of various chemical compounds. This helps scientists and researchers to better understand the underlying mechanisms of different chemical reactions and processes.
Used in Material Science:
In the field of material science, 3'-AMINO-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER is used as a component in the development of new materials with specific properties. Its incorporation into various materials can lead to the creation of innovative products with enhanced performance characteristics.
Overall, 3'-AMINO-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER is a versatile compound with a wide range of applications across different industries, including chemical synthesis, pharmaceuticals, research and development, and material science. Its unique properties and potential for use in various processes make it a valuable asset in the field of chemistry and related disciplines.

Upstream product

• 149506-24-1 3'-nitro-[1,1'-biphenyl]-3-carboxylic acid methyl ester 
• 618-89-3 methyl 3-bromobenzoate 
• 99769-19-4 [3-(methoxycarbonyl)phenyl]boronic acid 
• 585-79-5 m-nitrobromobenzene 
• 13331-27-6 m-nitrobenzene boronic acid 

Downstream Products

• 252921-55-4 (R)-3'-[[2-[[2-(3-chlorophenyl)-2-[[(tert-butyl)dimethylsilyl]oxy]ethyl][(tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester 

Relevant articles and documents

Design and synthesis of short amphiphilic cationic peptidomimetics based on biphenyl backbone as antibacterial agents

Antimicrobial peptides (AMPs) and their synthetic mimics have received recent interest as new alternatives to traditional antibiotics in attempts to overcome the rise of antibiotic resistance in many microbes. AMPs are part of the natural defenses of most living organisms and they also have a unique mechanism of action against bacteria. Herein, a new series of short amphiphilic cationic peptidomimetics were synthesized by incorporating the 3′-amino-[1,1′-biphenyl]-3-carboxylic acid backbone to mimic the essential properties of natural AMPs. By altering hydrophobicity and charge, we identified the most potent analogue 25g that was active against both Gram-positive Staphylococcus aureus (MIC = 15.6 μM) and Gram-negative Escherichia coli (MIC = 7.8 μM) bacteria. Cytoplasmic permeability assay results revealed that 25g acts primarily by depolarization of lipids in cytoplasmic membranes. The active compounds were also investigated for their cytotoxicity to human cells, lysis of lipid bilayers using tethered bilayer lipid membranes (tBLMs) and their activity against established biofilms of S. aureus and E. coli.

SOLABEGRON ZWITTERION AND USES THEREOF

This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods o

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Synthesis of the β3-adrenergic receptor agonist Solabegron and Analogous N-(2-Ethylamino)-β-amino alcohols from O-acylated cyanohydrins - expanding the scope of minor enantiomer recycling

A novel methodology to produce highly enantioenriched N-(2-ethylamino)-β-amino alcohols was developed. These compounds were obtained from O-(α-bromoacyl) cyanohydrins, which were synthesized by the minor enantiomer methodology employing a Lewis acid and a

Biarylaniline phenethanolamines as potent and selective β3 adrenergic receptor agonists

The synthesis of a series of phenethanolamine aniline agonists that contain an aniline ring on the right-hand side of the molecule substituted at the meta position with a benzoic acid or a pyridyl carboxylate is described. Several of the analogues (e.g.,

Therapeutic biaryl derivatives

The present invention relates to therapeutic biaryl derivatives of formula (I), and pharmaceutically acceptable derivatives thereof wherein R1is a phenyl, naphthyl, pyridyl, thiazolyl, phenoxymethyl, or pyrimidyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C1-6alkoxy, C1-6alkyl, nitro, cyano, hydroxymethyl, trifluoromethyl, —NR6R6, and —NHSO2R6, where each R6is independently hydrogen or C1-4alkyl; R2is hydrogen or C1-6alkyl; X is oxygen, sulfur, —NH, or —NC1-4alkyl; R3is cyano, tetrazol-5-yl, or —CO2R7where R7is hydrogen or C1-6alkyl; R4and R5are independently hydrogen, C1-6alkyl, —CO2H, —CO2C1-6alkyl, cyano, tetrazol-5-yl, halogen, trifluoromethyl, or C1-6alkoxy, or, when R4and R5are bonded to adjacent carbon atoms, R4and R5may, together with the carbon atoms to which they are bonded, form a fused5or6membered ring optionally containing one or two nitrogen, oxygen, or sulfur atoms; and Y is N or CH, to processes for their preparation and their use in the treatment of diseases susceptible to ameleoration by treatment with a beta-3adrenoceptor agonist.